Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (10): 1056-1065.doi: 10.3969/j.issn.1000-6621.2021.10.015
• Original Articles • Previous Articles Next Articles
ZHU Hui, FU Lei, ZHANG Wei-yan, WANG Bin, CHEN Xi, LU Yu()
Received:
2021-04-22
Online:
2021-10-10
Published:
2021-10-11
Contact:
LU Yu
E-mail:luyu4876@hotmail.com
ZHU Hui, FU Lei, ZHANG Wei-yan, WANG Bin, CHEN Xi, LU Yu. Preliminary study on pharmacokinetics/pharmacodynamics of five new anti-tuberculosis drugs in mice[J]. Chinese Journal of Antituberculosis, 2021, 43(10): 1056-1065. doi: 10.3969/j.issn.1000-6621.2021.10.015
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.10.015
组别 | 剂量(mg/kg) | 4周(g,$\bar{x}\pm s$) | t值 | P值 | 8周(g,$\bar{x}\pm s$) | t值 | P值 |
---|---|---|---|---|---|---|---|
对照组 | 21.44±1.07 | 21.86±0.85 | |||||
PA-824 | |||||||
L组 | 10 | 20.87±0.98 | -0.883 | 0.403 | 22.56±1.05 | 1.169 | 0.276 |
M组 | 30 | 21.97±0.57 | 0.972 | 0.359 | 23.04±0.81 | 2.261 | 0.054 |
H组 | 100 | 22.49±0.71 | 1.829 | 0.105 | 22.35±1.01 | 0.838 | 0.426 |
Dlm | |||||||
L组 | 2.5 | 21.56±0.37 | 0.241 | 0.816 | 22.56±0.85 | 1.306 | 0.228 |
M组 | 5 | 21.63±1.33 | 0.244 | 0.814 | 23.30±1.06 | 2.389 | 0.044 |
H组 | 10 | 21.39±1.05 | -0.078 | 0.940 | 21.51±1.03 | -0.577 | 0.580 |
Cfz | |||||||
L组 | 5 | 22.01±1.04 | 0.846 | 0.422 | 23.20±1.20 | 2.047 | 0.075 |
M组 | 10 | 21.08±1.82 | -0.385 | 0.710 | 22.41±1.18 | 0.854 | 0.418 |
H组 | 20 | 20.76±0.79 | -1.152 | 0.283 | 22.82±0.67 | 1.988 | 0.082 |
Bdq | |||||||
L组 | 6.25 | 22.14±1.12 | 1.016 | 0.339 | 22.10±0.48 | 0.556 | 0.593 |
M组 | 12.5 | 21.68±0.66 | 0.417 | 0.688 | 23.52±0.35 | 4.064 | 0.004 |
H组 | 25 | 21.32±1.05 | -0.188 | 0.855 | 22.78±0.66 | 1.923 | 0.091 |
PBTZ-169 | |||||||
L组 | 5 | 21.30±0.48 | -0.275 | 0.790 | 22.45±0.88 | 1.095 | 0.305 |
M组 | 10 | 21.37±0.38 | -0.138 | 0.894 | 23.66±0.69 | 3.690 | 0.006 |
H组 | 20 | 20.84±0.75 | -1.032 | 0.332 | 23.45±0.41 | 3.798 | 0.005 |
组别 | 剂量(mg/kg) | 4周时浓度(μg/ml,$\bar{x}\pm s$) | 8周时浓度(μg/ml,$\bar{x}\pm s$) | 参考MICa(μg/ml) |
---|---|---|---|---|
PA-824 | 0.07 | |||
L组 | 10 | 3.75±0.92 | 2.84±0.61 | |
M组 | 30 | 9.05±1.70 | 7.60±1.28 | |
H组 | 100 | 17.95±2.87 | 14.68±1.02 | |
Dlm | 0.004 | |||
L组 | 2.5 | 0.02±0.01 | 0.20±0.06 | |
M组 | 5 | 0.24±0.12 | 0.20±0.05 | |
H组 | 10 | 0.43±0.17 | 0.40±0.07 | |
Cfz | 0.24 | |||
L组 | 5 | 0.22±0.01 | 0.26±0.02 | |
M组 | 10 | 0.23±0.04 | 0.43±0.05 | |
H组 | 20 | 0.36±0.08 | 0.47±0.07 | |
Bdq | 0.022~0.05 | |||
L组 | 6.25 | 0.31±0.10 | 0.22±0.07 | |
M组 | 12.5 | 0.32±0.14 | 0.42±0.07 | |
H组 | 25 | 0.68±0.25 | 0.68±0.26 | |
PBTZ-169 | 0.4~0.5b | |||
L组 | 5 | 7.25±1.69b | 6.91±1.52b | |
M组 | 10 | 18.70±6.69b | 21.23±4.45b | |
H组 | 20 | 51.54±20.35b | 74.56±17.80b |
组别 | 剂量(mg/kg) | 肺(log10CFU,$\bar{x}\pm s$) | t值a | P值a | 脾(log10CFU,$\bar{x}\pm s$) | t值a | P值a | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
对照组 | |||||||||||||
治疗前14d | 4.70±0.11 | 1.48±0.00 | |||||||||||
治疗当天 | 5.21±0.08 | 3.60±0.18 | |||||||||||
治疗8周 | 4.90±0.16 | 3.08±0.44 | |||||||||||
PA-824 | |||||||||||||
L组 | 10 | 4.72±0.19 | -1.542 | 0.162 | 4/5为0,1只为2.08 | -5.775 | <0.001 | ||||||
M组 | 30 | 4.00±0.17 | -8.654 | <0.001 | 0 | -15.475 | <0.001 | ||||||
H组 | 100 | 2.24±0.22 | -21.951 | <0.001 | 0 | -15.475 | <0.001 | ||||||
Dlm | |||||||||||||
L组 | 2.5 | 4.75±0.20 | -1.255 | 0.245 | 4/5为0,1只为2.08 | -5.775 | <0.001 | ||||||
M组 | 5 | 4.55±0.14 | -3.627 | 0.007 | 4/5为0,1只为1.48 | -7.803 | <0.001 | ||||||
H组 | 10 | 3.54±0.16 | -13.574 | <0.001 | 0 | -15.475 | <0.001 | ||||||
Cfz | |||||||||||||
L组 | 5 | 4.07±0.12 | -9.405 | <0.001 | 2.47±0.19 | -2.799 | 0.023 | ||||||
M组 | 10 | 4.02±0.27 | -6.231 | <0.001 | 2.40±0.80 | -1.657 | 0.136 | ||||||
H组 | 20 | 3.41±0.28 | -10.397 | <0.001 | 2.06±0.23 | -4.538 | 0.002 | ||||||
Bdq | |||||||||||||
L组 | 6.25 | 4.61±0.15 | -2.918 | 0.019 | 2.90±0.33 | -0.731 | 0.485 | ||||||
M组 | 12.5 | 3.85±0.51 | -4.405 | 0.008 | 4/5为0,1只为2.38 | -5.045 | 0.001 | ||||||
H组 | 25 | 1.91±1.08 | -6.109 | <0.001 | 0 | -15.475 | <0.001 | ||||||
PBTZ-169 | |||||||||||||
L组 | 5 | 5.54±0.22 | 5.306 | 0.001 | 3.16±0.17 | 0.381 | 0.713 | ||||||
M组 | 10 | 4.71±0.23 | -1.505 | 0.171 | 0 | -15.475 | <0.001 | ||||||
H组 | 20 | 3.36±0.21 | -12.999 | <0.001 | 4/5为0,1只为1.48 | -7.803 | <0.001 |
[1] |
韦媛媛, 杨帆, 汤杰, 等. 抗结核药物的研究进展. 中国药科大学学报, 2020, 51(2): 231-239. doi: 10.11665/j.issn.1000-5048.20200215.
doi: 10.11665/j.issn.1000-5048.20200215 |
[2] |
Singh R, Dwivedi SP, Gaharwar US, et al. Recent updates on drug resistance in Mycobacterium tuberculosis. J Appl Microbiol, 2020, 128(6): 1547-1567. doi: 10.1111/jam.14478.
doi: 10.1111/jam.14478 pmid: 31595643 |
[3] |
Tiberi S, du Plessis N, Walzl G, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis, 2018, 18(7): e183-198. doi: 10.1016/S1473-3099(18)30110-5.
doi: 10.1016/S1473-3099(18)30110-5 |
[4] |
赵皎洁, 陆宇. 抗结核药物药代动力学/药效学的研究及进展. 中国防痨杂志, 2019, 41(6): 700-704. doi: 10.3969/j.issn.1000-6621.2019.06.020.
doi: 10.3969/j.issn.1000-6621.2019.06.020 |
[5] | World Health Organization. WHO consolidated guidelines for drug-resistant tuberculosis treatment (2020 update). Geneva: World Health Organization, 2020. |
[6] | Working Group on New TB Drugs. 2021 Global New TB Drug Pipeline[EB/OL]. [2021-03-30]. http://www.newtndrugs.org/pipeline/discovery. |
[7] |
时翠林, 牛广豪, 王霞芳, 等. 耐药结核病治疗药物研究进展. 中华结核和呼吸杂志, 2020, 43(1): 58-63. doi: 10.3760/cma.j.issn.1001-0939.2020.01.013.
doi: 10.3760/cma.j.issn.1001-0939.2020.01.013 |
[8] |
陈曦, 刘忠泉, 王彬, 等. 14种抗结核药物在巨噬细胞内的抗结核活性评价. 中国防痨杂志, 2019, 41(9): 993-998. doi: 10.3969/j.issn.1000-6621.2019.09.014.
doi: 10.3969/j.issn.1000-6621.2019.09.014 |
[9] |
Mallikaarjun S, Chapagain ML, Sasaki T, et al. Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother, 2020, 65(1): e01207-20. doi: 10.1128/AAC.01207-20.
doi: 10.1128/AAC.01207-20 |
[10] |
Alghamdi WA, Al-Shaer MH, Kipiani M, et al. Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis. J Antimicrob Chemother, 2021, 76(4): 1019-1024. doi: 10.1093/jac/dkaa550.
doi: 10.1093/jac/dkaa550 pmid: 33378452 |
[11] |
Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med, 2006, 3(11): e466. doi: 10.1371/journal.pmed.0030466.
doi: 10.1371/journal.pmed.0030466 URL |
[12] |
Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother, 2005, 49(6): 2289-2293. doi: 10.1128/AAC.49.6.2289-2293.2005.
doi: 10.1128/AAC.49.6.2289-2293.2005 URL |
[13] |
Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307(5707): 223-227. doi: 10.1126/science.1106753.
doi: 10.1126/science.1106753 pmid: 15591164 |
[14] |
Swanson RV, Adamson J, Moodley C, et al. Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis. Antimicrob Agents Chemother, 2015, 59(6): 3042-3051. doi: 10.1128/AAC.00260-15.
doi: 10.1128/AAC.00260-15 URL |
[15] |
Makarov V, Lechartier B, Zhang M, et al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med, 2014, 6(3): 372-383. doi: 10.1002/emmm.201303575.
doi: 10.1002/emmm.201303575 pmid: 24500695 |
[16] |
Lakshminarayana SB, Boshoff HI, Cherian J, et al. Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis. PLoS One, 2014, 9(8): e105222. doi: 10.1371/journal.pone.0105222.
doi: 10.1371/journal.pone.0105222 URL |
[17] |
Svensson EM, Karlsson MO. Modelling of mycobacterial load reveals bedaquiline’s exposure-response relationship in patients with drug-resistant TB. J Antimicrob Chemother, 2017, 72(12): 3398-3405. doi: 10.1093/jac/dkx317.
doi: 10.1093/jac/dkx317 pmid: 28961790 |
[18] |
Mariandyshev AO, Khokhlov AL, Smerdin SV, et al. The main results of clinical trials of the efficacy, safety and pharmacokinetics of the perspective anti-tuberculosis drug makozinone (PBTZ169). Ter Arkh, 2020, 92(3): 61-72. doi: 10.26442/00403660.2020.03.000621.
doi: 10.26442/00403660.2020.03.000621 |
[19] |
Ismail N, Omar SV, Ismail NA, et al. Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis. Data Brief, 2018, 20: 1975-1983. doi: 10.1016/j.dib.2018.09.057.
doi: 10.1016/j.dib.2018.09.057 pmid: 30306102 |
[1] | Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 Edition) [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 859-866. |
[2] | Beijing Chest Hospital, Capital Medical University, Editorial Board of Chinese Journal of Antituberculosis. Expert consensus on the therapeutic drug monitoring of anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 867-873. |
[3] | Chinese Antituberculosis Association. Expert consensus on detection and preventive treatment of latent tuberculosis infection in high-risk population [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 874-878. |
[4] | ZHOU Wen-qiang, ZHANG Shuang, CHU Nai-hui. Current status and prospect of all-oral treatment regimens for drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 879-882. |
[5] | PANG Yu, GAO Xing-hui, TANG Yi-wei, GAO Meng-qiu. Host immune responses-based methods for laboratory diagnosis and clinical application of tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 883-892. |
[6] | DING Cai-hong, XIONG Yu, WANG Qing, GAO Xu-sheng, HAO Yan. Study on the early efficacy and safety of the regimen containing bedaquiline in the treatment of multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 893-898. |
[7] | WU Guo-lan, GAO Jing-tao, CHEN Xiao-hong, CHEN Li-zhou, WENG Li-zhen, GUO Zhi-ping, CHEN Xiu-ping, LIN Jian-dong, CHEN Su-xia, GAO Meng-qiu, LIU Yu-hong. Short-term effectiveness and safety of a regimen containing bedaquiline in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 899-904. |
[8] | SHI Wen-hui, CHU Nai-hui. Resistance to fluoroquinolones and the influencing factors in patients with drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 905-909. |
[9] | ZHANG Ting, SU Qian, WU Cheng-guo, WANG Qing-ya, LEI Rong-rong, CHEN Jian. Analysis of direct medical costs and influencing factors of pulmonary tuberculosis patients in Chongqing [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 910-915. |
[10] | ZHAO Xiu-juan, MO Jing-lian, SUN Tao, LIU Lin, ZHONG Ye-teng, PEI Hua, XIA Qian-feng. Prevalence and correlated factors of drug-resistant pulmonary tuberculosis admitted to the designated medical institutions in Hainan Province from 2015 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 916-923. |
[11] | LIN Jian, LIN Shu-fang, DAI Zhi-song, ZHAO Yong, ZHOU Yin-fa, ZHANG Tian-lin, WEI Shu-zhen. Analysis of the drug resistance surveillance results of Mycobacterium tuberculosis in Fujian Province from 2016 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 924-928. |
[12] | LI Ting, HE Jin-ge, XIA Lan, CHEN Chuang, XIAO Yue, LU Jia, WANG Dan-xia. The impact of the COVID-19 epidemic on tuberculosis notification in Sichuan Province [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 929-938. |
[13] | YI Yi-hang, YU Rong, SHI Guo-min, MA Xiao-hua, XIAO Si-fang, SHUI Jian, FAN Ren-hua, XIANG Yan-gen. Analysis of the composition and phenotypes of intestinal flora in primary bacteriologically-confirmed pulmonary tuberculosis patients based on high-throughput sequencing of 16S rRNA V4 region [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 939-946. |
[14] | YU Xia, REN Ru-yan, WEN Shu-an, LIANG Qian, DONG Ling-ling, HUANG Hai-rong. Evaluation of in vitro antibacterial effects of 13 antibiotics against rapidly growing mycobacteria [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 947-951. |
[15] | ZHOU Ying-yu, FU Lei, ZHANG Wei-yan, WANG Bin, CHEN Xi, LU Yu, CHEN Xiao-you. Analysis and comparative study on the virulence of several drug-resistant Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 952-960. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||